Continuous Renal Replacement Therapy Global Market Report 2024

The continuous renal replacement therapy market size has grown rapidly in recent years. It will grow from $1.41 billion in 2023 to $1.57 billion in 2024 at a compound annual growth rate (CAGR) of 10.9%. The growth observed in the historic period can be attributed to several factors, including an increased demand for advanced continuous renal replacement therapy (CRRT) devices, a rise in the prevalence and incidence of acute kidney injury (AKI), an increase in the number of medical applications for CRRT, a high prevalence of co-morbidities among patients requiring CRRT, and ongoing research and development efforts in the field.

The continuous renal replacement therapy market size is expected to see rapid growth in the next few years. It will grow to $2.38 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The forecasted growth can be attributed to several factors, including increasing incidences of chronic kidney diseases, a rising prevalence of diabetes leading to kidney complications, a growing number of intensive care unit (ICU) admissions necessitating renal support, rising investments in healthcare infrastructure to support renal care services, and expanding applications of continuous renal replacement therapy (CRRT) in pediatric care. Major trends expected in the forecast period encompass rapid advancements in CRRT technology, launches of new CRRT technologies, ongoing technological advancements in the field, continuous product innovation, and the introduction of technologically advanced CRRT products catering to diverse patient needs.

The rise in chronic kidney diseases is poised to fuel the growth of the continuous renal replacement therapy market in the coming years. Chronic kidney disease (CKD) is a persistent condition characterized by a gradual decline in kidney function, resulting in the impaired removal of waste products from the bloodstream. Factors contributing to the increasing incidence of chronic kidney diseases include lifestyle shifts, aging demographics, and rising rates of diabetes and hypertension. Continuous renal replacement therapy is employed in managing acute exacerbations or complications of chronic kidney disease to regulate fluid balance and continually eliminate metabolic waste products. For example, as reported by the Centers for Disease Control and Prevention in July 2022, kidney disease affected approximately 15% of the US population, amounting to 37 million individuals. Additionally, the Australian Institute of Health and Welfare noted an increase in the prevalence of kidney replacement therapy from 94 to 95.4 per 100,000 population between 2019 and 2020. This trend underscores the growing demand for continuous renal replacement therapy.

Leading companies in the continuous renal replacement therapy market are focusing on developing advanced products such as continuous renal replacement therapy (CRRT) platforms to cater to customers with enhanced features. CRRT platforms encompass systems and technologies utilized in delivering CRRT, a dialysis method primarily prescribed for critically ill patients unable to undergo regular hemodialysis. For instance, Baxter International Inc. introduced the Prismax 2 platform in May 2021, designed to streamline the administration of continuous renal replacement therapy and other organ support therapies. This platform, featuring the Prismalung+ blood-gas exchanger from Baxter’s TrueVue digital health portfolio, offers hospitals the flexibility needed to address ICU challenges and includes extracorporeal carbon dioxide removal (ECCO2R) therapy for acute respiratory dysfunction management.

In December 2021, Baxter International Inc. completed the acquisition of Hillrom for $12.5 billion, strategically expanding its product range and expertise in hospital equipment and digital health. This acquisition strengthens Baxter’s position as a global leader in medical technology, aligning with its mission to revolutionize healthcare and improve patient care worldwide. Hillrom, a US-based provider of continuous renal replacement therapy, joins forces with Baxter to advance medical technology innovation and enhance patient outcomes.

Major companies operating in the continuous renal replacement therapy market are Medtronic Plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Toray Industries Inc., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, NxStage Medical Inc., Hillrom Holdings Inc., Gambro AB, JMS Co. Ltd., Quanta Dialysis Technologies Ltd., Bellco S.r.l., Ningbo Tianyi Medical Devices Co. Ltd., Cytosorbents Corporation, Kawasumi Laboratories Inc., Medica S.p.A., Infomed SA, Medites Pharma Spol. S.R.O, Nikkiso Co. Ltd., Anjue Medical Equipment Co. Ltd., Medcomp Systems Ltd.

North America was the largest region in the continuous renal replacement therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the continuous renal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the continuous renal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Continuous renal replacement therapy (CRRT) is a form of dialysis that provides gradual, ongoing blood filtration to help regulate levels of fluids, electrolytes, and waste products in critically ill patients with acute kidney injury (AKI) who are hemodynamically unstable. It plays a crucial role in managing fluid overload in critically ill patients, particularly those who cannot tolerate rapid fluid removal through intermittent hemodialysis due to cardiovascular instability.

The primary products in the continuous renal replacement therapy market are systems and consumables. A continuous renal replacement therapy (CRRT) system is a specialized medical device utilized in treating critically ill patients with AKI or other renal conditions. It offers various renal and non-renal therapies using different modalities such as slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). These therapies are administered to adults, pediatrics, and neonates in various settings including hospitals, ambulatory care centers, and homecare setups.

The continuous renal replacement therapy market research report is one of a series of new reports that provides continuous renal replacement therapy market statistics, including continuous renal replacement therapy industry global market size, regional shares, competitors with a continuous renal replacement therapy market share, detailed continuous renal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the continuous renal replacement therapy industry. This continuous renal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The continuous renal replacement therapy (CRRT) market consists of revenues earned by entities by providing services such as acute hemodialysis, aquapheresis, and fluid management. The market value includes the value of related goods sold by the service provider or included within the service offering. The continuous renal replacement therapy market also includes sales of dialysis catheters, dialysates, hemostatic agents, and airway clearance systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.